<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048787</url>
  </required_header>
  <id_info>
    <org_study_id>CBKM120C2113</org_study_id>
    <secondary_id>2013-003384-64</secondary_id>
    <nct_id>NCT02048787</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.</brief_title>
  <official_title>An Open-label, Single Dose, Multicenter Study to Evaluate the Pharmacokinetics and Safety of 50 mg Oral Buparlisib in Subjects With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics and safety of buparlisib following a single 50 mg oral&#xD;
      dose in subjects with moderate and severe renal impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameter Cmax</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the maximum plasma concentration (PK parameter Cmax). Cmax directly determined from the plasma concentration-time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter AUCinf</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter AUCinf (area under the plasma concentration-time curve from time 0 to infinity). AUC determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter AUC0-t</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter AU0-t (area under the plasma-concentration time curve from timepoint 0 to time t). AUC determined from the plasma concentration-time profile using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK parameter CL/F</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter CL/F (clearance).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine PK parameter CLR</measure>
    <time_frame>predose, 0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-48 h, 48-72 h, 72-96 h, 96-120 h, 120-144 h</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the urine clearance CLR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameter Tmax</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Tmax (time to reach maximum plasma concentration), directly determined from the plasma concentration-time profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameter T1/2</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter T1/2 (terminal half-life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameter Vz/F</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Vz/F (the apparent volume of distribution following extravascular administration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Protein Binding</measure>
    <time_frame>predose, 1 hour post-dose</time_frame>
    <description>Measurement of effect of renal impairment on plasma protein binding. Fraction of buparlisib unbound will be determined (Fu).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound plasma PK parameter Cmax,u</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Cmax,u (Cmax,u is the observed maximum unbound plasma concentration following administration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound plasma PK parameter AUCinf,u</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameters AUCinf,u (AUCinf,u is the area under the unbound plasma concentration-time curve extrapolated to infinity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound plasma PK parameter Vu/F</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Vu/F (the apparent unbound drug volume of distribution following extravascular administration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound plasma PK parameter CLu/F</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter CLu/F (the unbound systemic clearance from plasma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK parameter Ae0-t</measure>
    <time_frame>predose, 0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-48 h, 48-72 h, 72-96 h, 96-120 h, 120-144 h</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the urine PK parameter Ae0-t (the amount of unchanged buparlisib excreted into the urine from time 0 to a defined point in time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between PK parameters Cmax, AUCinf, AUC0-t, CL/F, urine CLR and renal function.</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Determination of the relationship between the primary PK parameters (Cmax, AUCinf, AUC0-t, CL/F and urine PK parameter CLR) and renal function parameters eGFR (estimated glomerular filtration rate using the equation from the Modification of Diet in Renal Disease (MDRD) study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events severity and frequency</measure>
    <time_frame>Baseline Day 1 to 30 days post-dose</time_frame>
    <description>Assessment of safety and tolerability of a single dose buparlisib in renal impaired subjects compared with healthy control subjects by assessing the frequency and severity of Adverse Events based on the CTCAE criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory parameters</measure>
    <time_frame>From baseline Day 1 to 30 days post-dose</time_frame>
    <description>Assessment of safety and tolerability of a single dose buparlisib in renal impaired subjects compared with healthy control subjects by assessing the change from baseline in hematological and biochemical laboratory parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG parameters</measure>
    <time_frame>From baseline Day 1 to 30 days post-dose</time_frame>
    <description>Assessment of safety and tolerability of a single dose buparlisib in renal impaired subjects compared with healthy control subjects by assessing the change from baseline in ECG parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound plasma PK parameter AUC0-t,u</measure>
    <time_frame>predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose</time_frame>
    <description>Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameters AUC0-t,u (AUC0-t,u is the area under the unbound plasma concentration-time curve from time zero to time t).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Moderate renal impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching healthy control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buparlisib</intervention_name>
    <description>Subjects will receive a single dose of 50 mg buparlisib.</description>
    <arm_group_label>Matching healthy control group</arm_group_label>
    <arm_group_label>Moderate renal impairment group</arm_group_label>
    <arm_group_label>Severe renal impairment group</arm_group_label>
    <other_name>BKM120</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Other than renal impairment, subjects should be in good health as determined by past&#xD;
             medical history, physical examination, vital signs, electrocardiogram, (except for&#xD;
             additional inclusion criteria for renal impaired patients).&#xD;
&#xD;
          -  Subjects must have a BMI between 18 kg/m2 and 34 kg/m2 and weight at least 50 kg and&#xD;
             no more than 120 kg.&#xD;
&#xD;
               -  Additional criteria for renal impaired subjects: - Subjects must have stable&#xD;
                  renal disease without evidence of renal progressive disease defined as moderate&#xD;
                  renal impairment (eGFR 30-59 mL/min/1.73m2) or severe renal impairment (eGFR&#xD;
                  15-29 mL/min/1.73m2).&#xD;
&#xD;
               -  Additional criteria for matched healthy control subjects: - Matched to at least&#xD;
                  one renal impaired subject by gender, race, age (± 10 years), and weight (± 20%).&#xD;
&#xD;
          -  An estimated GFR as determined by MDRD equation within normal range as determined by&#xD;
             eGFR ≥ 90 mL/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant illness, including infections, or hospitalization within the 2 weeks prior&#xD;
             to dosing, except for the renal impaired subjects who due to their renal disease may&#xD;
             be affected by significant medical problems which require frequent hospitalizations.&#xD;
&#xD;
          -  Any surgical or medical condition that may significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, or which may jeopardize the subject&#xD;
             in case of participation in the study&#xD;
&#xD;
          -  Subject has a medical history of cardiac disease and/or clinically significant ECG&#xD;
             abnormalities within 6 months prior to screening.&#xD;
&#xD;
          -  Subject has an active or a history within 6 months prior to screening of clinically&#xD;
             significant hematologic, endocrinologic, pulmonary, cardiovascular, hepatic, or&#xD;
             allergic disease, medically documented (other than clinical conditions associated with&#xD;
             renal impairment for the renal impaired subjects only).&#xD;
&#xD;
          -  - Additional exclusion criteria for renal impaired subjects: - Severe albuminuria &gt;&#xD;
             300 mg/day.&#xD;
&#xD;
          -  Subjects undergoing any method of dialysis.&#xD;
&#xD;
          -  Subjects with renal impairment due to hepatic disease (hepatorenal syndrome).&#xD;
&#xD;
          -  Subjects with clinically significant abnormal findings, not consistent with clinical&#xD;
             disease, upon physical examination, ECG or laboratory evaluation.&#xD;
&#xD;
          -  Use of any prescription or non-prescription medication that has the potential to&#xD;
             interact with buparlisib within two weeks prior to dosing or during the study.&#xD;
&#xD;
          -  - Additional criteria for matched healthy control subjects: - Use of any prescription&#xD;
             or non-prescription medication or vitamins during 14 days prior to dosing.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Russian Federation</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14390</url>
    <description>Results can be found for CBKM120C2113 on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal impairment</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Clinical pharmacology study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

